LENETTE BALTAZAR: Open Payments
NPI 1851028245 · WAUKEGAN, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,214 in 35 payments from 10 companies in 2025. Trend: 2023 $707 · 2024 $1,581 · 2025 $1,214
Food & beverage: $1,214
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 8 | $327 |
| Otsuka America Pharmaceutical, Inc. | 10 | $309 |
| E.R. Squibb & Sons, L.L.C. | 1 | $136 |
| Lundbeck LLC | 5 | $117 |
| ViiV Healthcare Company | 1 | $110 |
| Janssen Pharmaceuticals, Inc | 3 | $56 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $46 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $45 |
| Luye Pharma (USA) Ltd. | 2 | $42 |
| Alkermes, Inc. | 1 | $27 |
Products named: UZEDY, REXULTI, ABILIFY ASIMTUFII, COBENFY, APRETUDE, INVEGA SUSTENNA, CAPLYTA, ERZOFRI EXTENDED-RELEASE.
Industry payments across IL — which companies pay providers there.
